BOSTON & MONTREAL, October 01, 2024–(BUSINESS WIRE)–enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of September 30, 2024.
The inducement awards consist of a non-qualified stock options to purchase an aggregate 183,000 of the Company’s common shares. The options each have an exercise price of $6.60 per share, which is equal to the closing price of the Company’s common shares on September 30, 2024, the date of grant. Each stock option has a 10-year term and will vest over four…
